Journal of global antimicrobial resistance · 2025
Therapeutic potential of novel phages with antibiotic combinations against ESBL-producing and carbapenem-resistant Escherichia Coli.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shamsuzzaman Md, Kim Shukho, Kim Jungmin
Аннотация
OBJECTIVES: The emergence of extended-spectrum β-lactamase (ESBL)-producing E. coli and carbapenem-resistant E. coli (CREC) is a significant global health challenge. This study focuses on isolating and characterizing two novel phages, EC.W1-9 and EC.W15-4, and investigating their efficacy with antibiotics against these resistant E. coli.
METHODS: In vivo experiments were conducted using BALB/c mice, and E.coli isolates were collected, cultured, and evaluated for antibiotic susceptibility. Phages were isolated from hospital sewage and prepared to infect the E. coli.
RESULTS: The isolated phages, EC.W1-9 and EC.W15-4, belonged to the Podoviridae and Straboviridae families, and lack integrase or toxin-coding genes, indicating safety for therapeutic use. The combination of these phages significently enhanced their lytic ability, lysing 61.7% of 60 E. coli isolates, compared to 41.6%-55% lysis by individual phages. Furthermore, the phage combination demonstrated 100% susceptibility against different E. coli sequence types, including ST73, ST648, ST2311, ST405, ST7962, ST131, ST13003, and ST167. Additionally, synergy between antibiotics and phage combinations improved susceptibility rates to 73.3% for ESBL producers and 54% for CREC. The combined treatment of isolated phages and antibiotics significantly increased survival rates in BALB/c mice exposed to resistant STs of E.coli, including ST131, ST648, and ST410. Survival rates against ST131 increased by approximately 75% and 50% compared to treatment individual phages. Combined treatment with two phages and antibiotics resulted in 75-100% survival against E. coli ST410 and 100% survival against ST648 CONCLUSIONS: This study highlights the therapeutic importance of phage and phage-antibiotic combinations in combating ESBL-producing E. coli and CREC isolates.
METHODS: In vivo experiments were conducted using BALB/c mice, and E.coli isolates were collected, cultured, and evaluated for antibiotic susceptibility. Phages were isolated from hospital sewage and prepared to infect the E. coli.
RESULTS: The isolated phages, EC.W1-9 and EC.W15-4, belonged to the Podoviridae and Straboviridae families, and lack integrase or toxin-coding genes, indicating safety for therapeutic use. The combination of these phages significently enhanced their lytic ability, lysing 61.7% of 60 E. coli isolates, compared to 41.6%-55% lysis by individual phages. Furthermore, the phage combination demonstrated 100% susceptibility against different E. coli sequence types, including ST73, ST648, ST2311, ST405, ST7962, ST131, ST13003, and ST167. Additionally, synergy between antibiotics and phage combinations improved susceptibility rates to 73.3% for ESBL producers and 54% for CREC. The combined treatment of isolated phages and antibiotics significantly increased survival rates in BALB/c mice exposed to resistant STs of E.coli, including ST131, ST648, and ST410. Survival rates against ST131 increased by approximately 75% and 50% compared to treatment individual phages. Combined treatment with two phages and antibiotics resulted in 75-100% survival against E. coli ST410 and 100% survival against ST648 CONCLUSIONS: This study highlights the therapeutic importance of phage and phage-antibiotic combinations in combating ESBL-producing E. coli and CREC isolates.